Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: omega-3-ethyl esters Clear all
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 17, 2026, 6:09 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

NCT02926027
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Vascepa, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 17, 2026, 6:09 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

NCT01191177
View directory record Official record
Conditions
Liver Disease, Short Bowel Syndrome
Interventions
Lovaza (omega-3-acid ethyl ester), Corn oil
Drug · Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

NCT00935766
View directory record Official record
Conditions
Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
Interventions
Omega-3, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Babu Balagopal
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Fish Oil in Lupus Patients

NCT00828178
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Omega-3, flow-mediated dilation of the brachial artery, corn starch
Drug · Device · Other
Lead sponsor
Michelle Petri M.D.,MPH
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Immunonutrition for Diabetic Foot Ulcers

NCT05281562
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions
Lovaza, L-Arginine Powder, Vitamin C
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pro-Resolving Mediators in Acute Inflammation in Humans

NCT04308889
View directory record Official record
Conditions
Inflammation; Skin, Resolution, Blister
Interventions
Lovaza, Cantharone, Phlebotomy
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363
View directory record Official record
Conditions
Fibrillation, Atrial
Interventions
omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
178
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content

NCT01369550
View directory record Official record
Conditions
Healthy Volunteers, Markers of Cardiovascular Risk
Interventions
SDA soybean oil-containing foods, High-oleic sunflower oil containing foods, Eicosapentaenoic acid
Other
Lead sponsor
Monsanto Company, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Sep 17, 2026, 6:09 PM EDT
Withdrawn Phase 2 Interventional

OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

NCT03661047
View directory record Official record
Conditions
Colon Cancer
Interventions
AMR101 (VASCEPA, icosapent ethyl)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega 7 + 3 Combination and Systemic Inflammation

NCT02155816
View directory record Official record
Conditions
Inflammation
Interventions
Omega 7 + 3, Omega 3, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

NCT06434948
View directory record Official record
Conditions
Postoperative Delirium
Interventions
Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
View directory record Official record
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

NCT00001146
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Ethyl Eicosapentaenoic Acid, OmegaBrite
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229
View directory record Official record
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Sep 17, 2026, 6:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Omacor and Aspirin on Platelet Function

NCT00688961
View directory record Official record
Conditions
Healthy
Interventions
Aspirin, omega-3 acid ethyl esters
Drug
Lead sponsor
Sanford Research
Other
Eligibility
21 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2008 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Fish Oil on Post Ablation Arrhythmias

NCT00791089
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
LOVAZA Omega 3-acid ethyl esters, LOVAZA, placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 17, 2026, 6:09 PM EDT
Withdrawn Early Phase 1 Interventional

Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue

NCT01784042
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Lovaza, Dietary energy restriction
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
30 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 17, 2026, 6:09 PM EDT
Terminated Phase 2 Interventional Results available

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT00845845
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Interventions
Omega-3-acid ethyl esters (Lovaza), Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Sep 17, 2026, 6:09 PM EDT